Internal Medicine, Infectious Disease · Springfield, MA
NPI
1609834662
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
57 Mulberry St.
Springfield, MA, 01105
Phone (413) 747-5566
Groups this clinician bills Medicare through
Medicare paid, 2024
$221K
11,001 services
Medicare patients, 2024
73
Average age 65
Drug cost, 2024
$5.1M
1,933 prescriptions
Company payments, 2025
$165K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Claudia T Martorell was code 99214 (office e&m - established), 135 times for 55 patients. In total Claudia T Martorell billed 11,001 services in 15 codes, and Medicare paid $221K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 135 | 55 | $90.08 | $12K |
| 99213 Office E&M - Established | Office | 68 | 34 | $60.62 | $4,122 |
| 99442 Telephone Services | Office | 45 | 27 | $69.98 | $3,149 |
By year: 2022 $29K for 472 services; 2023 $23K for 377 services; 2024 $221K for 11,001 services.
Medicare prescription drug claims, 2024
In 2024, the drug Claudia T Martorell prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 265 prescriptions and refills. In total Claudia T Martorell wrote 1,933 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 265 | 277 | 29 | $1.1M |
| Dovato Dolutegravir Sodium/Lamivudine | 203 | 219 | 25 | $642K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 141 | 163 | 17 | $621K |
| Valacyclovir Valacyclovir Hcl | 98 | 133 | 19 | $2,203 |
| Descovy Emtricitabine/Tenofov Alafenam | 88 | 88 | 13 | $199K |
| Tivicay Dolutegravir Sodium | 74 | 84 | Under 11 | $235K |
| Fluconazole Generic | 71 | 72 | 22 | $662 |
| Doxycycline Hyclate Generic | 71 | 71 | 24 | $796 |
| Cabenuva Cabotegravir/Rilpivirine | 68 | 110 | 15 | $415K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 63 | 63 | Under 11 | $223K |
| Juluca Dolutegravir/Rilpivirine | 56 | 56 | Under 11 | $198K |
| Egrifta Sv Tesamorelin Acetate | 47 | 47 | Under 11 | $345K |
| Omeprazole Generic | 38 | 74 | Under 11 | $389 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 37 | 45 | Under 11 | $352 |
| Nystatin Generic | 35 | 38 | 14 | $883 |
Brand drugs: 1,206 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Claudia T Martorell $165K ($165K in general payments such as food, travel and fees) from 6 companies. The largest payer was ViiV Healthcare Company with $90K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.